Talquetamab JNJ-64407564|cas:2226212-40-2|西域试剂

Talquetamab JNJ-64407564,96.44%

产品编号：Bellancom-P99394| CAS NO：2226212-40-2

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P99394	￥3500.00	杭州北京（现货）
Bellancom-P99394	￥8750.00	杭州北京（现货）
Bellancom-P99394	￥14000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Talquetamab JNJ-64407564

产品介绍

Talquetamab（JNJ-64407564）是一种人源化的双特异性抗体，可与 GPRC5D(G 蛋白偶联受体家族C5组成员 D) 和 CD3 结合，通过T 细胞的募集和活化诱导 T 细胞介导的杀死表达 GPRC5 的 MM 细胞。Talquetamab（JNJ-64407564）具有抗肿瘤活性。

生物活性

Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity.

体外研究

Talquetamab (0.00128-4.0 μg/mL, 48 h) 有效诱导多发性骨髓瘤细胞裂解，并导致活化的 CD⁴⁺ 和CD⁸⁺ T 细胞比例显著增加，以及颗粒酶 B 和炎症细胞因子如 IL-6、IL-8 和 TNF-α 水平的剂量依赖性增加.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Talquetamab (JNJ-64407564) (0.1-50 µg, s.c. or i.v.)在 H929 和 MM 小鼠模型中有明显的抗肿瘤活性。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female NSG mice with H929 cells
Dosage:	0.1-10 µg (0.005 mg/kg)
Administration:	Subcutaneous injection; on days 0, 3, 5, 7, and 10
Result:	Completely blocked tumor formation at 1 μg and 10 μg doses.

Animal Model:	Female NSG mice with human MM cells
Dosage:	0.1-50 µg (0.005 mg/kg)
Administration:	Intravenous injection; on days 15, 18, 22, 24, 29, 32, and 36
Result:	Significantly inhibited tumor growth by 65% at the dose of 1μg and showed significant anti-tumor activity at 10 and 50 μg with complete tumor regression.

体内研究

Talquetamab (JNJ-64407564) (0.1-50 µg, s.c. or i.v.)在 H929 和 MM 小鼠模型中有明显的抗肿瘤活性。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female NSG mice with H929 cells
Dosage:	0.1-10 µg (0.005 mg/kg)
Administration:	Subcutaneous injection; on days 0, 3, 5, 7, and 10
Result:	Completely blocked tumor formation at 1 μg and 10 μg doses.

Animal Model:	Female NSG mice with human MM cells
Dosage:	0.1-50 µg (0.005 mg/kg)
Administration:	Intravenous injection; on days 15, 18, 22, 24, 29, 32, and 36
Result:	Significantly inhibited tumor growth by 65% at the dose of 1μg and showed significant anti-tumor activity at 10 and 50 μg with complete tumor regression.